NEW YORK, September 19, 2016 /PRNewswire/ --
The NASDAQ Composite ended the trading session at 5,244.57, down 0.10 on Friday, September 16, 2016. Today, Stock-Callers.com looks at the performance of the following biotech companies for the recent few weeks: Ocular Therapeutix Inc. (NASDAQ: OCUL), Infinity Pharmaceuticals Inc. (NASDAQ: INFI), Lpath Inc. (NASDAQ: LPTN), and Idera Pharmaceuticals Inc. (NASDAQ: IDRA). You can access of our complimentary research reports on these stocks now at:
Bedford, Massachusetts headquartered Ocular Therapeutix Inc.'s stock finished Friday's session 2.12% higher at $6.75 with a total volume of 778,112 shares traded. Ocular Therapeutix's shares have surged 25.00% in the past three months. The Company's shares are trading above its 50-day moving average by 12.94%. Shares of Ocular Therapeutix, which focuses on the development and commercialization of therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology in the US, have a Relative Strength Index (RSI) of 52.78. Visit us today and download your complete report on OCUL for free at:
Cambridge, Massachusetts headquartered Infinity Pharmaceuticals Inc.'s stock advanced 4.29%, to close the day at $1.46. The stock recorded a trading volume of 993,706 shares. Shares of Infinity Pharma, which discovers, develops, and delivers medicines to patients with difficult-to-treat diseases, are trading 6.12% and 68.48% below its 50-day and 200-day moving averages, respectively. Additionally, the stock traded at a PE ratio of 5.03 and has an RSI of 44.30. The complimentary research report on INFI can be accessed at:
On Friday, shares in San Diego, California-based Lpath Inc. ended the session 8.30% higher at $3.13 with a total volume of 218,802 shares traded. Lpath's shares have surged 52.68% in the last one month and 50.48% in the past three months. Furthermore, the stock has advanced 6.46% in the previous one year. The stock is trading 41.98% and 20.33% above its 50-day and 200-day moving averages, respectively. Moreover, shares of the Company, which focuses on the discovery and development of lipidomic-based therapeutic antibodies to treat a range of human diseases in the US, have an RSI of 70.31. Register for free on Stock-Callers.com and download the PDF research report on LPTN at:
On Friday, shares in Cambridge, Massachusetts-based Idera Pharmaceuticals Inc. recorded a trading volume of 1.80 million shares, which was higher than their three months average volume of 455,820 shares. The stock ended the day 8.00% higher at $2.16. Idera Pharma's stock has gained 11.92% in the last one month and 40.26% in the previous three months. The company is trading above its 50-day and 200-day moving averages by 17.85% and 8.47%, respectively. Furthermore, shares of Idera Pharma, which focuses on the discovery, development, and commercialization of therapeutics for oncology and rare diseases in the US, have an RSI of 70.97. Get free access to your research report on IDRA at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: firstname.lastname@example.org Phone number: +44 330 808 3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA